Literature DB >> 21400009

Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.

Dimitris J Apostolopoulos1, Antonia Dimitrakopoulou-Strauss, Peter Hohenberger, Safwan Roumia, Ludwig G Strauss.   

Abstract

PURPOSE: (18)F-Fluorodeoxyglucose positron emission tomography (FDG PET) may underestimate viable tumour tissue in patients with gastrointestinal stromal tumours (GIST) treated with molecular targeted agents. The aim of the present study was to investigate the value of parametric images generated after dynamic data acquisition for the detection of active liver metastases.
METHODS: The analysis included 65 dynamic FDG PET studies in 34 patients with liver metastases from GIST who were treated with imatinib or sunitinib. Parametric images of intercept and slope were calculated by dedicated software using a voxel-based linear regression of time-activity data. Intercept images represent the tracer's distribution volume and the slope its overall metabolic turnover. All images were assessed visually and semi-quantitatively. Liver disease status was established 12 months after each PET study. Dichotomous variables of visual interpretation and various quantitative parameters were entered in a statistical model of linear discriminant analysis.
RESULTS: Visual analysis of slope images was more sensitive than the standard 1-h FDG uptake evaluation (70.6 vs 51.0%, p = 0.016) in detecting cases with liver disease progression (n = 51). Specificity did not differ. Combination of all variables in the discriminant analysis model correctly classified 87.7% of cases as progressive or non-progressive disease. Sensitivity was raised to 88.2%.
CONCLUSION: Parametric images of intercept and slope add a new dimension to the interpretation of FDG PET studies, by isolating visually and quantifying the perfusion and phosphorylation-dependent part of tracer uptake. In treated GIST patients, integration of this information with the 1-h uptake data achieves better characterization of hepatic lesions with respect to disease activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400009     DOI: 10.1007/s00259-011-1776-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

Review 1.  How should we analyse FDG PET studies for monitoring tumour response?

Authors:  Adriaan A Lammertsma; Corneline J Hoekstra; Giuseppe Giaccone; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

2.  Requirements and implementation of a flexible kinetic modeling tool.

Authors:  C Burger; A Buck
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

Review 3.  Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers.

Authors:  Stefan Duensing; Anette Duensing
Journal:  Biochem Pharmacol       Date:  2010-04-10       Impact factor: 5.858

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

5.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

6.  Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?

Authors:  Egbert U Nitzsche; Stefan Hoegerle; Michael Mix; Ingo Brink; Andreas Otte; Ernst Moser; Andreas Imdahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

7.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

8.  Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Authors:  Courtney L Scaife; Kelly K Hunt; Shreyaskumar R Patel; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; A Kevin Raymond; Janice N Cormier; Peter W T Pisters; Raphael E Pollock; Barry W Feig
Journal:  Am J Surg       Date:  2003-12       Impact factor: 2.565

9.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.

Authors:  Robert K Doot; Lisa K Dunnwald; Erin K Schubert; Mark Muzi; Lanell M Peterson; Paul E Kinahan; Brenda F Kurland; David A Mankoff
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  5 in total

1.  (18)F-Deoxyglucose (FDG) kinetics evaluated by a non-compartment model based on a linear regression function using a computer based simulation: correlation with the parameters of the two-tissue compartment model.

Authors:  Ludwig G Strauss; Leyun Pan; Caixia Cheng; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

2.  [PET-CT for nuclear medicine diagnostics of multiple myeloma].

Authors:  A Dimitrakopoulou-Strauss
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

3.  [Importance of PET for surgery of gastrointestinal stromal tumors].

Authors:  U Ronellenfitsch; B Wängler; S Niedermoser; A Dimitrakopoulou-Strauss; P Hohenberger
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

4.  Correlation of dynamic PET and gene array data in patients with gastrointestinal stromal tumors.

Authors:  Ludwig G Strauss; Antonia Dimitrakopoulou-Strauss; Dirk Koczan; Leyun Pan; Peter Hohenberger
Journal:  ScientificWorldJournal       Date:  2012-06-04

Review 5.  Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.

Authors:  Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ludwig G Strauss
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.